ArticleGlobal & regional health technology assessment

A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy.

Marco Bellone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.